Sustained exposure to multivalent antigen-decorated nanoparticles generates broad anti-coronavirus responses
- PMID: 40821443
- PMCID: PMC12352413
- DOI: 10.1016/j.matt.2025.102006
Sustained exposure to multivalent antigen-decorated nanoparticles generates broad anti-coronavirus responses
Abstract
The threat of future coronavirus pandemics requires developing effective vaccine technologies that provide broad and long-lasting protection against circulating and emerging strains. Here we report a multivalent liposomal hydrogel vaccine technology comprising the receptor binding domain (RBD) of up to four SARS and MERS coronavirus strains non-covalently displayed on the surface of the liposomes within the hydrogel structure. The multivalent presentation and sustained exposure of RBD antigens improved the potency, neutralizing activity, durability, and consistency of antibody responses across homologous and heterologous coronavirus strains in a naïve murine model. When administrated in animals pre-exposed to wild-type SARS-CoV-2 antigens, liposomal hydrogels elicited durable antibody responses against the homologous SARS and MERS strains for over six months and elicited neutralizing activity against the immune-evasive SARS-CoV-2 variant Omicron BA.4/BA.5. Overall, the tunable liposomal hydrogel platform we report here generates robust responses against diverse coronaviruses, supporting global efforts to respond to future viral outbreaks.
Keywords: Coronavirus; Drug Delivery; Hydrogels; Liposomes; Vaccines.
Conflict of interest statement
Declaration of interest E.A.A. and J.H.K. are listed as inventors on a patent application describing the technology reported in this manuscript. E.A.A. is a co-founder, equity holder, and advisor of Appel Sauce Studios, which holds an exclusive license to the technology reported in this manuscript. All other authors have no interests to declare.
Similar articles
-
Design of SARS-CoV-2 RBD immunogens to focus immune responses toward conserved coronavirus epitopes.J Virol. 2025 Jul 22;99(7):e0046525. doi: 10.1128/jvi.00465-25. Epub 2025 Jun 13. J Virol. 2025. PMID: 40511920 Free PMC article.
-
Lumazine Synthase Nanoparticles as a Versatile Platform for Multivalent Antigen Presentation and Cross-Protective Coronavirus Vaccines.ACS Nano. 2025 Aug 12;19(31):28295-28314. doi: 10.1021/acsnano.5c06081. Epub 2025 Jul 31. ACS Nano. 2025. PMID: 40745975
-
Immunogenicity of monovalent and multivalent subunit vaccines against SARS-CoV-2 variants in mice with divergent vaccination history.Microbiol Spectr. 2025 Aug 5;13(8):e0290724. doi: 10.1128/spectrum.02907-24. Epub 2025 Jul 17. Microbiol Spectr. 2025. PMID: 40673708 Free PMC article.
-
SARS-CoV-2-neutralising monoclonal antibodies to prevent COVID-19.Cochrane Database Syst Rev. 2022 Jun 17;6(6):CD014945. doi: 10.1002/14651858.CD014945.pub2. Cochrane Database Syst Rev. 2022. PMID: 35713300 Free PMC article.
-
Effectiveness of COVID-19 vaccines against SARS-CoV-2 infection and severe outcomes in adults: a systematic review and meta-analysis of European studies published up to 22 January 2024.Eur Respir Rev. 2025 Feb 19;34(175):240222. doi: 10.1183/16000617.0222-2024. Print 2025 Jan. Eur Respir Rev. 2025. PMID: 39971395 Free PMC article.
References
-
- Pardi N, and Krammer F (2024). mRNA vaccines for infectious diseases — advances, challenges and opportunities. Nature Reviews Drug Discovery 23, 838. - PubMed
-
- Moyle PM, and Toth I (2013). Modern Subunit Vaccines: Development, Components, and Research Opportunities. ChemMedChem 8, 360. - PubMed
-
- Ou BS, Saouaf OM, Baillet J, and Appel EA (2022). Sustained delivery approaches to improving adaptive immune responses. Advanced Drug Delivery Reviews 187, 114401. - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources
Miscellaneous